Modest reductions in systolic blood pressure (BP), inflammation, and lipid concentrations as well as significant reduction in body weight have been observed in patients treated with GLP-1 RAs, and they have, therefore, been suggested as candidates for use in patients with diabetes at high risk of CV disease (CVD).7 This evidence concerns the gene GLP1R and diabetes mellitus.